CBD for Individuals at Risk for Alzheimer's Disease

Summary

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

Timeline

Start

2024-01-19

Primary completion

2028-04

Completion

2029-04

Drugs

Indications